COLL vs LXRX: stock comparison and AI forecast
Collegium Pharmaceutical, Inc (COLL) and Lexicon Pharmaceuticals, Inc. (LXRX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
COLL Collegium Pharmaceutical, Inc
- Price
- $25.16 -36.0% · 6M
- Market Cap
- $819M
- P/E Ratio
- 16.9x
- Size
- small-cap
- AI Forecast
LXRX Lexicon Pharmaceuticals, Inc.
- Price
- $1.78 +6.0% · 6M
- Market Cap
- $792M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- COLL and LXRX have similar market capitalizations ($819M and $792M).
- Over the last six months LXRX returned +6.0% and COLL -36.0%.
- COLL turns 4.7% of its revenue into net income, against -161.8% for LXRX.
- COLL carries 6.07 times debt per unit of equity, against 0.48 times for LXRX.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | COLL | LXRX |
|---|---|---|
| Market Cap | $819M | $792M |
| P/E Ratio | 16.88x | – |
| P/B Ratio | 2.76x | 4.83x |
| EPS | $1.49 | $-0.13 |
| Book Value/Share | $9.11 | $0.37 |
| Revenue/Share | $25.04 | $0.09 |
| FCF/Share | $10.33 | – |
Profitability & Margins
| Metric | COLL | LXRX |
|---|---|---|
| ROE | 12.9% | -38.1% |
| ROA | 1.8% | -25.8% |
| ROIC | 8.3% | -25.3% |
| Gross Margin | 59.0% | – |
| Operating Margin | 15.2% | -147.4% |
| Net Margin | 4.7% | -161.8% |
| EBT Margin | 5.2% | -147.4% |
| Tax Rate | 9.4% | – |
Financial Health
| Metric | COLL | LXRX |
|---|---|---|
| Current Ratio | 1.01x | 10.63x |
| Quick Ratio | 0.87x | 10.56x |
| D/E Ratio | 6.07x | 0.48x |
| Financial Leverage | 7.07x | 1.48x |
| Interest Coverage | 1.1x | -10.5x |
| Working Capital | $9M | $171M |
Cash Flow
| Metric | COLL | LXRX |
|---|---|---|
| Operating Cash Flow | $338M | -$49M |
| Free Cash Flow | $336M | – |
| Capital Spending | -$2M | – |
| OCF Growth YoY | 16.2% | – |
| FCF Growth YoY | 16.2% | – |
| FCF/Sales | 41.2% | – |
| CapEx/Sales | 0.2% | – |
Operational Efficiency
| Metric | COLL | LXRX |
|---|---|---|
| Asset Turnover | 0.39x | 0.16x |
| Receivables Turnover | 2.6x | 21.7x |
| Inventory Turnover | 3.8x | 0.3x |
| Fixed Assets Turnover | 75.0x | 24.8x |
| Days Sales Outstanding | 139 days | 17 days |
| Days Inventory | 96 days | 1031 days |
| Payables Period | 11 days | 3629 days |
| Cash Conversion Cycle | 224 days | -2581 days |
Income Statement
| Metric | COLL | LXRX |
|---|---|---|
| Total Revenue | $815M | $39M |
| Operating Income | $124M | -$57M |
| Net Income | $38M | -$62M |
| R&D Expense | – | $58M |
| SG&A Expense | $360M | $37M |
| Cost of Goods Sold | $334M | $430K |
Dividend & Shareholder Information
| Metric | COLL | LXRX |
|---|---|---|
| Shares Outstanding | 33M | 445M |
| Net Income Growth | -34.7% | – |
| EPS Growth | -22.0% | – |
COLL vs LXRX: stock comparison and AI forecast
Which is bigger, COLL or LXRX?
COLL and LXRX have similar market capitalizations ($819M and $792M).
Which stock performed better over the last six months, COLL or LXRX?
Over the last six months LXRX returned +6.0% and COLL -36.0%.
Which one does Intratio's AI model rank higher, COLL or LXRX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.